Hypomagnesemia in type 2 diabetes: A vicious circle?

Diabetes

Volumn 65, Issue 1, 2016, Pages 3-13

  Gommers, Lisanne M M ^a   Hoenderop, Joost G J ^a   Bindels, René J M ^a   De Baaij, Jeroen H F ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATE; CALCIUM CHANNEL L TYPE; GLUCOKINASE; GLUCOSE; GLUCOSE 6 PHOSPHATE; GLUCOSE TRANSPORTER 4; GLYCOGEN; INSULIN; INSULIN RECEPTOR; INTERLEUKIN 1; MAGNESIUM ION; POTASSIUM CHANNEL; POTASSIUM CHANNEL KIR4.1; SODIUM CHLORIDE COTRANSPORTER; TRANSIENT RECEPTOR POTENTIAL CHANNEL M6; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; GLUCOSE BLOOD LEVEL; INWARDLY RECTIFYING POTASSIUM CHANNEL; KCNJ10 (CHANNEL); MAGNESIUM;

ARTICLE; AUTOPHOSPHORYLATION; DIABETES MELLITUS; DISEASE ASSOCIATION; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; GLYCOLYSIS; HOMEOSTASIS; HUMAN; HYPOMAGNESEMIA; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY TUBULE ABSORPTION; MAGNESIUM BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BINDING; BIOSYNTHESIS; COMPLICATION; DIETARY SUPPLEMENT; DISEASE COURSE; GLUCOSE BLOOD LEVEL; LIVER; MAGNESIUM DEFICIENCY; METABOLISM; SECRETION (PROCESS); WATER-ELECTROLYTE IMBALANCE;

BLOOD GLUCOSE; CALCIUM CHANNELS, L-TYPE; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; GLUCOKINASE; GLYCOGEN; GLYCOLYSIS; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; KATP CHANNELS; LIVER; MAGNESIUM; MAGNESIUM DEFICIENCY; OBESITY; POTASSIUM CHANNELS, INWARDLY RECTIFYING; SODIUM CHLORIDE SYMPORTERS; SODIUM-POTASSIUM-EXCHANGING ATPASE; WATER-ELECTROLYTE IMBALANCE;

EID: 84962161391     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-1028     Document Type: Article

References (129)

1. Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman Med J 2012;27:269-273
2. Bergman M. Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. Endocrine 2013;43:504-513
3. Martin HE, Wertman M. Serum potassium, magnesium, and calcium levels in diabetic acidosis. J Clin Invest 1947;26:217-228
4. Pham PC, Pham PM, Pham SV, Miller JM, Pham PT. Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2007;2:366-373
5. Chaudhary DP, Sharma R, Bansal DD. Implications of magnesium deficiency in type 2 diabetes: a review. Biol Trace Elem Res 2010;134:119-129
6. Pham PC, Pham PM, Pham PA, et al. Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2. Clin Nephrol 2005;63:429-436
7. Dong JY, Xun P, He K, Qin LQ. Magnesium intake and risk of type 2 diabetes: meta-analysis of prospective cohort studies. Diabetes Care 2011;34: 2116-2122
8. Guerrero-Romero F, Rodríguez-Morán M. Oral magnesium supplementation: an adjuvant alternative to facing the worldwide challenge of type 2 diabetes? Cir Cir 2014;82:282-289 [in Spanish]
9. Guerrero-Romero F, Simental-Mendía LE, Hernández-Ronquillo G, Rodriguez-Morán M. Oral magnesium supplementation improves glycaemic status in subjects with prediabetes and hypomagnesaemia: a double-blind placebo-controlled randomized trial. Diabetes Metab 2015;41:202-207
10. Rodríguez-Morán M, Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care 2003;26:1147-1152
11. Rodríguez-Morán M, Simental Mendia LE, Zambrano Galvan G, Guerrero-Romero F. The role of magnesium in type 2 diabetes: a brief based-clinical review. Magnes Res 2011;24:156-162
12. de Baaij JHF, Hoenderop JGJ, Bindels RJM. Magnesium in man: implications for health and disease. Physiol Rev 2015;95:1-46
13. Barbagallo M, Dominguez LJ. Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance. Arch Biochem Biophys 2007;458:40-47
14. Fröjdö S, Vidal H, Pirola L. Alterations of insulin signaling in type 2 diabetes: a review of the current evidence from humans. Biochim Biophys Acta 2009;1792:83-92
15. Rodríguez-Morán M, Guerrero-Romero F. Insulin secretion is decreased in non-diabetic individuals with hypomagnesaemia. Diabetes Metab Res Rev 2011; 27:590-596
16. 2+ in insulin secretion, insulin signal transduction and insulin resistance. Magnes Res 2010;23:5-18
17. Takaya J, Higashino H, Kobayashi Y. Intracellular magnesium and insulin resistance. Magnes Res 2004;17:126-136
18. Barbagallo M, Dominguez LJ, Galioto A, et al. Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome X. Mol Aspects Med 2003;24:39-52
19. Guyton AC, Hall JE. Textbook of Medical Physiology. 11th ed. Philadelphia, Saunders, 2006
20. Humphries S, Kushner H, Falkner B. Low dietary magnesium is associated with insulin resistance in a sample of young, nondiabetic Black Americans. Am J Hypertens 1999;12:747-756
21. Lima MdeL, Cruz T, Rodrigues LE, et al. Serum and intracellular magnesium deficiency in patients with metabolic syndrome-evidences for its relation to insulin resistance. Diabetes Res Clin Pract 2009;83:257-262
22. Nadler JL, Buchanan T, Natarajan R, Antonipillai I, Bergman R, Rude R. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension 1993;21:1024-1029
23. Hubbard SR. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 1997;16: 5572-5581
24. Vicario PP, Bennun A. Separate effects of Mg2+, MgATP, and ATP4- on the kinetic mechanism for insulin receptor tyrosine kinase. Arch Biochem Biophys 1990;278:99-105
25. Viñals F, Camps M, Testar X, Palacín M, Zorzano A. Effect of cations on the tyrosine kinase activity of the insulin receptor: inhibition by fluoride is magnesium dependent. Mol Cell Biochem 1997;171:69-73
26. Paxton R, Ye L. Regulation of heart insulin receptor tyrosine kinase activity by magnesium and spermine. Mol Cell Biochem 2005;277:7-17
27. Suárez A, Pulido N, Casla A, Casanova B, Arrieta FJ, Rovira A. Impaired tyrosine-kinase activity of muscle insulin receptors from hypomagnesaemic rats. Diabetologia 1995;38:1262-1270
28. Reis MA, Reyes FG, Saad MJ, Velloso LA. Magnesium deficiency modulates the insulin signaling pathway in liver but not muscle of rats. J Nutr 2000; 130:133-138
29. Biddinger SB, Kahn CR. From mice to men: insights into the insulin resistance syndromes. Annu Rev Physiol 2006;68:123-158
30. Solaimani H, Soltani N, MaleKzadeh K, et al. Modulation of GLUT4 expression by oral administration of Mg(2+) to control sugar levels in STZ-induced diabetic rats. Can J Physiol Pharmacol 2014;92:438-444
31. Ha BG, Park JE, Cho HJ, Shon YH. Stimulatory effects of balanced deep sea water on mitochondrial biogenesis and function. PLoS One 2015;10: e0129972
32. McNeill DA, Herbein JH, Ritchey SJ. Hepatic gluconeogenic enzymes, plasma insulin and glucagon response to magnesium deficiency and fasting. J Nutr 1982;112:736-743
33. Takaya J, Iharada A, Okihana H, Kaneko K. Down-regulation of hepatic phosphoenolpyruvate carboxykinase expression in magnesium-deficient rats. Magnes Res 2012;25:131-139
34. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997;389:610-614
35. de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett 2008;582:97-105
36. Weglicki WB, Phillips TM, Freedman AM, Cassidy MM, Dickens BF. Magnesium-deficiency elevates circulating levels of inflammatory cytokines and endothelin. Mol Cell Biochem 1992;110:169-173
37. Rodriguez-Moran M, Guerrero-Romero F. Elevated concentrations of TNF-alpha are related to low serum magnesium levels in obese subjects. Magnes Res 2004;17:189-196
38. Bussière FI, Gueux E, Rock E, et al. Increased phagocytosis and production of reactive oxygen species by neutrophils during magnesium deficiency in rats and inhibition by high magnesium concentration. Br J Nutr 2002;87:107-113
39. Rodríguez-Morán M, Guerrero-Romero F. Serum magnesium and C-reactive protein levels. Arch Dis Child 2008;93:676-680
40. Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. Oral magnesium supplementation decreases C-reactive protein levels in subjects with prediabetes and hypomagnesemia: a clinical randomized double-blind placebo-controlled trial. Arch Med Res 2014;45:325-330
41. Henriksen EJ, Diamond-Stanic MK, Marchionne EM. Oxidative stress and the etiology of insulin resistance and type 2 diabetes. Free Radic Biol Med 2011; 51:993-999
42. 2+ signals promote GLUT4 exocytosis and reduce its endocytosis in muscle cells. Am J Physiol Endocrinol Metab 2014;307: E209-E224
43. Takaya J, Yamato F, Higashino H, Kaneko K. Intracellular magnesium and adi-pokines in umbilical cord plasma and infant birth size. Pediatr Res 2007;62:700-703
44. Matschinsky FM. Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics. Diabetes 2002;51(Suppl. 3):S394-S404
45. Ashcroft FM, Rorsman P. K(ATP) channels and islet hormone secretion: new insights and controversies. Nat Rev Endocrinol 2013;9:660-669
46. Braun M, Ramracheya R, Bengtsson M, et al. Voltage-gated ion channels in human pancreatic beta-cells: electrophysiological characterization and role in insulin secretion. Diabetes 2008;57:1618-1628
47. Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 2004;53(Suppl. 3):S16-S21
48. Meier JJ, Bonadonna RC. Role of reduced β-cell mass versus impaired β-cell function in the pathogenesis of type 2 diabetes. Diabetes Care 2013;36 (Suppl. 2):S113-S119
49. Billings LK, Florez JC. The genetics of type 2 diabetes: what have we learned from GWAS? Ann N Y Acad Sci 2010;1212:59-77
50. Randell EW, Mathews M, Gadag V, Zhang H, Sun G. Relationship between serum magnesium values, lipids and anthropometric risk factors. Atherosclerosis 2008;196:413-419
51. Guerrero-Romero F, Rodríguez-Morán M. Magnesium improves the beta-cell function to compensate variation of insulin sensitivity: double-blind, randomized clinical trial. Eur J Clin Invest 2011;41:405-410
52. Molnes J, Teigen K, Aukrust I, et al. Binding of ATP at the active site of human pancreatic glucokinase-nucleotide-induced conformational changes with possible implications for its kinetic cooperativity. FEBS J 2011;278:2372-2386
53. Storer AC, Cornish-Bowden A. Kinetics of rat liver glucokinase. Co-operative interactions with glucose at physiologically significant concentrations. Biochem J 1976;159:7-14
54. Garfinkel L, Garfinkel D. Magnesium regulation of the glycolytic pathway and the enzymes involved. Magnesium 1985;4:60-72
55. Laughlin MR, Thompson D. The regulatory role for magnesium in glycolytic flux of the human erythrocyte. J Biol Chem 1996;271:28977-28983
56. Ashcroft FM, Harrison DE, Ashcroft SJ. Glucose induces closure of single potassium channels in isolated rat pancreatic beta-cells. Nature 1984;312:446-448
57. Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Invest 2005;115:2047-2058
58. Proks P, de Wet H, Ashcroft FM. Sulfonylureas suppress the stimulatory action of Mg-nucleotides on Kir6.2/SUR1 but not Kir6.2/SUR2A KATP channels: a mechanistic study. J Gen Physiol 2014;144:469-486
59. Ashcroft FM. New uses for old drugs: neonatal diabetes and sulphonylureas. Cell Metab 2010;11:179-181
60. Schulla V, Renström E, Feil R, et al. Impaired insulin secretion and glucose tolerance in beta cell-selective Ca(v)1.2 Ca2+ channel null mice. EMBO J 2003; 22:3844-3854
61. Nitert MD, Nagorny CL, Wendt A, Eliasson L, Mulder H. CaV1.2 rather than CaV1.3 is coupled to glucose-stimulated insulin secretion in INS-1 832/13 cells. J Mol Endocrinol 2008;41:1-11
62. Wang M, Berlin JR. Channel phosphorylation and modulation of L-type Ca2+ currents by cytosolic Mg2+ concentration. Am J Physiol Cell Physiol 2006; 291:C83-C92
63. Wang M, Tashiro M, Berlin JR. Regulation of L-type calcium current by intracellular magnesium in rat cardiac myocytes. J Physiol 2004;555:383-396
64. Zhang J, Berra-Romani R, Sinnegger-Brauns MJ, Striessnig J, Blaustein MP, Matteson DR. Role of Cav1.2 L-type Ca2+ channels in vascular tone: effects of nifedipine and Mg2+. Am J Physiol Heart Circ Physiol 2007;292:H415-H425
65. Shimaoka T, Wang Y, Morishima M, Miyamoto S, Ono K. Hypomagnesemic down-regulation of L-type Ca(2+) channel in cardiomyocyte as an arrhythmogenic substrate in rats. Pathophysiology 2015;22:87-93
66. Atwater I, Frankel BJ, Rojas E, Grodsky GM. Beta cell membrane potential and insulin release; role of calcium and calcium:magnesium ratio. Q J Exp Physiol 1983;68:233-245
67. Balon TW, Gu JL, Tokuyama Y, Jasman AP, Nadler JL. Magnesium supplementation reduces development of diabetes in a rat model of spontaneous NIDDM. Am J Physiol 1995;269:E745-E752
68. Rubin H. The membrane, magnesium, mitosis (MMM) model of cell proliferation control. Magnes Res 2005;18:268-274
69. Chan KH, Chacko SA, Song Y, et al. Genetic variations in magnesium-related ion channels may affect diabetes risk among African American and Hispanic American women. J Nutr 2015;145:418-424
70. Romero JR, Castonguay AJ, Barton NS, Germer S, Martin M, Zee RY. Gene variation of the transient receptor potential cation channel, subfamily M, members 6 (TRPM6) and 7 (TRPM7), and type 2 diabetes mellitus: a case-control study. Transl Res 2010;156:235-241
71. Song Y, Hsu YH, Niu T, Manson JE, Buring JE, Liu S. Common genetic variants of the ion channel transient receptor potential membrane melastatin 6 and 7 (TRPM6 and TRPM7), magnesium intake, and risk of type 2 diabetes in women. BMC Med Genet 2009;10:4
72. Paolisso G, Sgambato S, Passariello N, et al. Insulin induces opposite changes in plasma and erythrocyte magnesium concentrations in normal man. Diabetologia 1986;29:644-647
73. Gylfe E. Insulin secretagogues induce Ca(2+)-like changes in cytoplasmic Mg2+ in pancreatic beta-cells. Biochim Biophys Acta 1990;1055:82-86
74. Romani AM, Matthews VD, Scarpa A. Parallel stimulation of glucose and Mg(2+) accumulation by insulin in rat hearts and cardiac ventricular myocytes. Circ Res 2000;86:326-333
75. Schlingmann KP, Weber S, Peters M, et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet 2002;31:166-170
76. Walder RY, Landau D, Meyer P, et al. Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. Nat Genet 2002;31:171-174
77. Groenestege WM, Hoenderop JG, van den Heuvel L, Knoers N, Bindels RJ. The epithelial Mg2+ channel transient receptor potential melastatin 6 is regulated by dietary Mg2+ content and estrogens. J Am Soc Nephrol 2006;17:1035-1043
78. Li M, Du J, Jiang J, et al. Molecular determinants of Mg2+ and Ca2+ permeability and pH sensitivity in TRPM6 and TRPM7. J Biol Chem 2007;282: 25817-25830
79. Cao G, van der Wijst J, van der Kemp A, van Zeeland F, Bindels RJ, Hoenderop JG. Regulation of the epithelial Mg2+ channel TRPM6 by estrogen and the associated repressor protein of estrogen receptor activity (REA). J Biol Chem 2009;284:14788-14795
80. Thebault S, Alexander RT, Tiel Groenestege WM, Hoenderop JG, Bindels RJ. EGF increases TRPM6 activity and surface expression. J Am Soc Nephrol 2009;20:78-85
81. de Baaij JH, Blanchard MG, Lavrijsen M, Leipziger J, Bindels RJ, Hoenderop JG. P2X4 receptor regulation of transient receptor potential melastatin type 6 (TRPM6) Mg2+ channels. Pflugers Arch 2014;466:1941-1952
82. de Baaij JH, Dorresteijn EM, Hennekam EA, et al. Recurrent FXYD2 p.Gly41Arg mutation in patients with isolated dominant hypomagnesaemia. Nephrol Dial Transplant 2015;30:952-957
83. Glaudemans B, van der Wijst J, Scola RH, et al. A missense mutation in the Kv1.1 voltage-gated potassium channel-encoding gene KCNA1 is linked to human autosomal dominant hypomagnesemia. J Clin Invest 2009;119:936-942
84. Reichold M, Zdebik AA, Lieberer E, et al. KCNJ10 gene mutations causing EAST syndrome (epilepsy, ataxia, sensorineural deafness, and tubulopathy) disrupt channel function. Proc Natl Acad Sci U S A 2010;107:14490-14495
85. Arjona FJ, de Baaij JH, Schlingmann KP, et al. CNNM2 mutations cause impaired brain development and seizures in patients with hypomagnesemia. PLoS Genet 2014;10:e1004267
86. Hurd TW, Otto EA, Mishima E, et al. Mutation of the Mg2+ transporter SLC41A1 results in a nephronophthisis-like phenotype. J Am Soc Nephrol 2013; 24:967-977
87. 2+ exchanger. Am J Physiol Cell Physiol 2012; 302:C318-C326
88. McNair P, Christensen MS, Christiansen C, Madsbad S, Transbøl I. Renal hypomagnesaemia in human diabetes mellitus: its relation to glucose homeo-stasis. Eur J Clin Invest 1982;12:81-85
89. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J 1922;12:141-146
90. Atchley DW, Loeb RF, Richards DW, Benedict EM, Driscoll ME. On diabetic acidosis: a detailed study of electrolyte balances following the withdrawal and reestablishment of insulin therapy. J Clin Invest 1933;12:297-326
91. Aikaws JK. Effect of glucose and insulin on magnesium metabolism in rabbits. A study with Mg28. Proc Soc Exp Biol Med 1960;103:363-366
92. Mandon B, Siga E, Chabardes D, Firsov D, Roinel N, De Rouffignac C. Insulin stimulates Na+, Cl-, Ca2+, and Mg2+ transports in TAL of mouse nephron: cross-potentiation with AVP. Am J Physiol 1993;265:F361-F369
93. Dai LJ, Ritchie G, Bapty BW, Kerstan D, Quamme GA. Insulin stimulates Mg2+ uptake in mouse distal convoluted tubule cells. Am J Physiol 1999;277: F907-F913
94. Nair AV, Hocher B, Verkaart S, et al. Loss of insulin-induced activation of TRPM6 magnesium channels results in impaired glucose tolerance during pregnancy. Proc Natl Acad Sci U S A 2012;109:11324-11329
95. Hruby A, Ngwa JS, Renström F, et al. Higher magnesium intake is associated with lower fasting glucose and insulin, with no evidence of interaction with select genetic loci, in a meta-analysis of 15 CHARGE Consortium Studies. J Nutr 2013;143:345-353
96. Lee CT, Lien YH, Lai LW, Chen JB, Lin CR, Chen HC. Increased renal calcium and magnesium transporter abundance in streptozotocin-induced diabetes mellitus. Kidney Int 2006;69:1786-1791
97. Takayanagi K, Shimizu T, Tayama Y, et al. Down-regulation of transient receptor potential (TRP) M6 channel as a cause of hypermagnesiuric hypo-magnesemia in obese type-2 diabetic rats. Am J Physiol Renal Physiol 2015;308: F1386-F1397
98. de Baaij JH, Groot Koerkamp MJ, Lavrijsen M, et al. Elucidation of the distal convoluted tubule transcriptome identifies new candidate genes involved in renal Mg(2+) handling. Am J Physiol Renal Physiol 2013;305:F1563-F1573
99. Chávez-Canales M, Arroyo JP, Ko B, et al. Insulin increases the functional activity of the renal NaCl cotransporter. J Hypertens 2013;31:303-311
100. Komers R, Rogers S, Oyama TT, et al. Enhanced phosphorylation of Na(+)-Cl-co-transporter in experimental metabolic syndrome: role of insulin. Clin Sci (Lond) 2012;123:635-647
101. Nishida H, Sohara E, Nomura N, et al. Phosphatidylinositol 3-kinase/Akt signaling pathway activates the WNK-OSR1/SPAK-NCC phosphorylation cascade in hyperinsulinemic db/db mice. Hypertension 2012;60:981-990
102. Sohara E, Rai T, Yang SS, et al. Acute insulin stimulation induces phos-phorylation of the Na-Cl cotransporter in cultured distal mpkDCT cells and mouse kidney. PLoS One 2011;6:e24277
103. Takahashi D, Mori T, Nomura N, et al. WNK4 is the major WNK positively regulating NCC in the mouse kidney. Biosci Rep 2014;34:34
104. Schutta MH. Diabetes and hypertension: epidemiology of the relationship and pathophysiology of factors associated with these comorbid conditions. J Cardiometab Syndr 2007;2:124-130
105. Knoers NV, Levtchenko EN. Gitelman syndrome. Orphanet J Rare Dis 2008;3:22
106. Davies DL, Fraser R. Do diuretics cause magnesium deficiency? Br J Clin Pharmacol 1993;36:1-10
107. Ishii M, Horio Y, Tada Y, et al. Expression and clustered distribution of an inwardly rectifying potassium channel, KAB-2/Kir4.1, on mammalian retinal Müller cell membrane: their regulation by insulin and laminin signals. J Neurosci 1997;17:7725-7735
108. Zhang Y, Xu G, Ling Q, Da C. Expression of aquaporin 4 and Kir4.1 in diabetic rat retina: treatment with minocycline. J Int Med Res 2011;39:464-479
109. Bockenhauer D, Feather S, Stanescu HC, et al. Epilepsy, ataxia, sensori-neural deafness, tubulopathy, and KCNJ10 mutations. N Engl J Med 2009;360: 1960-1970
110. Scholl UI, Choi M, Liu T, et al. Seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance (SeSAME syndrome) caused by mutations in KCNJ10. Proc Natl Acad Sci U S A 2009;106:5842-5847
111. Galuska D, Kotova O, Barrès R, Chibalina D, Benziane B, Chibalin AV. Altered expression and insulin-induced trafficking of Na+-K+-ATPase in rat skeletal muscle: effects of high-fat diet and exercise. Am J Physiol Endocrinol Metab 2009;297:E38-E49
112. Rosta K, Tulassay E, Enzsoly A, et al. Insulin induced translocation of Na+/K+ -ATPase is decreased in the heart of streptozotocin diabetic rats. Acta Pharmacol Sin 2009;30:1616-1624
113. Vague P, Coste TC, Jannot MF, Raccah D, Tsimaratos M. C-peptide, Na+,K(+)-ATPase, and diabetes. Exp Diabesity Res 2004;5:37-50
114. Sweeney G, Klip A. Regulation of the Na+/K+-ATPase by insulin: why and how? Mol Cell Biochem 1998;182:121-133
115. Alves DS, Thulin G, Loffing J, Kashgarian M, Caplan MJ. Akt substrate of 160 kD regulates Na+,K+-ATPase trafficking in response to energy depletion and renal ischemia. J Am Soc Nephrol 2015;26:2765-2776
116. Lennon EJ, Lemann J Jr, Piering WF, Larson LS. The effect of glucose on urinary cation excretion during chronic extracellular volume expansion in normal man. J Clin Invest 1974;53:1424-1433
117. Roy DR, Seely JF. Effect of glucose on renal excretion of electrolytes in the rat. Am J Physiol 1981;240:F17-F24
118. Ly JP, Onay T, Sison K, et al. The Sweet Pee model for Sglt2 mutation. J Am Soc Nephrol 2011;22:113-123
119. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014;129:587-597
120. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin mono-therapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33:2217-2224
121. Ahloulay M, Schmitt F, Déchaux M, Bankir L. Vasopressin and urinary concentrating activity in diabetes mellitus. Diabetes Metab 1999;25:213-222
122. Premaratne E, Verma S, Ekinci EI, Theverkalam G, Jerums G, MacIsaac RJ. The impact of hyperfiltration on the diabetic kidney. Diabetes Metab 2015; 41:5-17
123. Le Grimellec C. Micropuncture study along the proximal convoluted tubule. Electrolyte reabsorption in first convolutions. Pflugers Arch 1975;354: 133-150
124. Singh DK, Winocour P, Farrington K. Oxidative stress in early diabetic nephropathy: fueling the fire. Nat Rev Endocrinol 2011;7:176-184
125. Cao G, Lee KP, van der Wijst J, et al. Methionine sulfoxide reductase B1 (MsrB1) recovers TRPM6 channel activity during oxidative stress. J Biol Chem 2010;285:26081-26087
126. Li Y, Zhang W, Li P, Huang K. Effect of streptozocin-induced diabetes mellitus on expression of methionine sulfoxide reductases and accumulation of their substrates in mouse lenses. Exp Eye Res 2011;92:401-407
127. Dasgupta A, Sarma D, Saikia UK. Hypomagnesemia in type 2 diabetes mellitus. Indian J Endocrinol Metab 2012;16:1000-1003
128. Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hy-pomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther 2012;36:405-413
129. Lameris AL, Monnens LA, Bindels RJ, Hoenderop JG. Drug-induced alterations in Mg2+ homoeostasis. Clin Sci (Lond) 2012;123:1-14